{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:55:40Z","timestamp":1758124540802},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The purpose of this study was to assess an institution\u2019s heparin protocols in elderly and nonelderly adult populations to see if a response difference was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective cohort study of hospitalized adults who were prescribed unfractionated heparin due to surgery, acute coronary syndrome (ACS), or deep vein thrombosis\/pulmonary embolism (DVT\/PE) from February 11, 2016, through August 1, 2017. Patients were divided into nonelderly adults 18 to 69 years of age and elderly patients 70 years of age or older. The anti-factor Xa (anti-Xa) level after protocol initiation was compared to the institution\u2019s goal range of 0.3 to 0.7 IU\/mL. Outcomes of each protocol in the elderly population were compared to outcomes in their nonelderly counterparts to determine if there was a difference in heparin response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 325 patients were included in the analysis, comprising 150 elderly and 175 nonelderly adults. Elderly patients had a higher initial anti-Xa levels than did their nonelderly adult counterparts in the ACS, DVT\/PE, and surgery protocols, with P values of 0.02, &amp;lt;0.001, and 0.01, respectively. Only the ACS protocol demonstrated increased frequency of above-target-level anti-Xa levels in the elderly (P = 0.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Elderly patients had significantly higher initial anti-Xa levels than did nonelderly adult patients across all protocols. This study identifies the need to further study elderly patients\u2019 increased heparin sensitivity to determine if a separate dosing protocol is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz304","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T08:37:08Z","timestamp":1580114228000},"page":"S13-S18","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating anticoagulation sensitivity among elderly patients managed with an institution\u2019s heparin protocol using initial anti-factor Xa levels"],"prefix":"10.1093","volume":"77","author":[{"given":"Adley","family":"Lemke","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hennepin Healthcare, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Kohs","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hennepin Healthcare, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Weber","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hennepin Healthcare, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"2020021903592854300_CIT0001","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"2020021903592854300_CIT0002","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"issue":"9","key":"2020021903592854300_CIT0003","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"issue":"8","key":"2020021903592854300_CIT0004","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archinte.1996.00440080047006","article-title":"Aging and heparin-related bleeding","volume":"156","author":"Campbell","year":"1996","journal-title":"Arch Intern Med"},{"issue":"7","key":"2020021903592854300_CIT0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1076029613485153","article-title":"Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age","volume":"20","author":"Kim","year":"2013","journal-title":"Clin Appl Thromb Hemos"},{"issue":"9","key":"2020021903592854300_CIT0006","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00134-014-3406-5","article-title":"A data-driven approach to optimized medication dosing: a focus on heparin","volume":"40","author":"Ghassemi","year":"2014","journal-title":"Intensive Care Med"},{"issue":"7","key":"2020021903592854300_CIT0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40266-016-0378-x","article-title":"Drug treatment of venous thromboembolism in the elderly","volume":"33","author":"Boey","year":"2016","journal-title":"Drugs Aging"},{"issue":"9","key":"2020021903592854300_CIT0008","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00002512-200219090-00002","article-title":"Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation","volume":"19","author":"Patel","year":"2002","journal-title":"Drugs Aging"},{"issue":"7368","key":"2020021903592854300_CIT0009","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.325.7368.828","article-title":"Bleeding risks of antithrombotic therapy","volume":"325","author":"Fitzmaurice","year":"2002","journal-title":"BMJ"},{"issue":"8","key":"2020021903592854300_CIT0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/00002512-200623080-00003","article-title":"Management of venous thromboembolism in the elderly","volume":"23","author":"Spyropoulos","year":"2006","journal-title":"Drugs Aging"},{"issue":"9","key":"2020021903592854300_CIT0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40266-013-0101-0","article-title":"Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly","volume":"30","author":"Siguret","year":"2013","journal-title":"Drugs Aging"},{"issue":"3","key":"2020021903592854300_CIT0012","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11239-015-1255-x","article-title":"Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin","volume":"41","author":"Kikkert","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"2020021903592854300_CIT0013","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2146\/sp150016","article-title":"Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring","volume":"72","author":"Frug\u00e9","year":"2015","journal-title":"Am J Health-Syst Pharm"},{"issue":"5","key":"2020021903592854300_CIT0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2146\/ajhp090123","article-title":"Weight-based heparin protocol using antifactor Xa monitoring","volume":"67","author":"Smith","year":"2010","journal-title":"Am J Health-Syst Pharm"},{"issue":"6","key":"2020021903592854300_CIT0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2020021903592854300_CIT0016","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group","year":"2013","journal-title":"Kid Int Suppl (2011)"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/Supplement_1\/S13\/32516748\/zxz304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/Supplement_1\/S13\/32516748\/zxz304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T03:59:40Z","timestamp":1582084780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/Supplement_1\/S13\/5716290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":16,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,1,27]]},"published-print":{"date-parts":[[2020,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz304","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2020,1,27]]}}}